PCI-32765: A novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies

Expert Opinion on Investigational Drugs

Volumn 21, Issue 3, 2012, Pages 355-361

  Winer, Eric S ^a   Ingham, Randall R ^b   Castillo, Jorge J ^b  

^a RHODE ISLAND HOSPITAL   (United States)

^b MIRIAM HOSPITAL   (United States)

Author keywords

Bruton's tyrosine kinase; Leukemia; Lymphoma

Indexed keywords

B LYMPHOCYTE RECEPTOR; BENDAMUSTINE; BORTEZOMIB; BRENTUXIMAB VEDOTIN; BRUTON TYROSINE KINASE; CD79A ANTIGEN; CD79B ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; FLUDARABINE PHOSPHATE; I KAPPA B; IMMUNOGLOBULIN G; MICRORNA; OFATUMUMAB; PCI 32765; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; UNCLASSIFIED DRUG;

B CELL LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; SMALL INTESTINE OBSTRUCTION; VIRUS INFECTION;

ANIMALS; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES;

EID: 84856877017     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.656199     Document Type: Review

References (51)

1. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with lowgrade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-76 (Pubitemid 29022402)
2. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-74
3. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463:88-92
4. Mahadevan D, Fisher RI. Novel therapeutics for aggressive non-Hodgkin's lymphoma. J Clin Oncol 2011;29:1876-84
5. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-85
6. Brad K, Flinn I, Wagner-Johnston N. S, et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110, in patients with relapsed or refractory non-Hodgkin lymphoma [ASH annual meeting abstract 1777]. Blood 2010;116:21
7. Smith CI, Islam TC, Mattsson PT, et al. The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. Bioessays 2001;23:436-46 (Pubitemid 32453973)
8. Mohamed AJ, Yu L, Backesjo CM, et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 2009;228:58-73
9. Nisitani S, Satterthwaite AB, Akashi K, et al. Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells. Proc Natl Acad Sci USA 2000;97:2737-42 (Pubitemid 30159241)
10. de Weers M, Verschuren MC, Kraakman ME, et al. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages. Eur J Immunol 1993;23:3109-14 (Pubitemid 23353756)
11. Smith CI, Baskin B, Humire-Greiff P, et al. Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol 1994;152:557-65 (Pubitemid 24072959)
12. Conley ME, Dobbs AK, Farmer DM, et al. Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol 2009;27:199-227
13. Lindvall JM, Blomberg KE, Wennborg A, Smith CI. Differential expression and molecular characterisation of Lmo7, Myo1e, Sash1, and Mcoln2 genes in Btk-defective B-cells. Cell Immunol 2005;235:46-55 (Pubitemid 41483033)
14. Vetrie D, Vorechovsky I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993;361:226-33 (Pubitemid 23034471)
15. Plebani A, Soresina A, Rondelli R, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol 2002;104:221-30 (Pubitemid 35191097)
16. Howard V, Greene JM, Pahwa S, et al. The health status and quality of life of adults with X-linked agammaglobulinemia. Clin Immunol 2006;118:201-8 (Pubitemid 43199659)
17. Rawlings DJ, Saffran DC, Tsukada S, et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science 1993;261:358-61 (Pubitemid 23281007)
18. Thomas JD, Sideras P, Smith CI, et al. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science 1993;261:355-8 (Pubitemid 23281006)
19. Suzuki H, Terauchi Y, Fujiwara M, et al. Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase. Science 1999;283:390-2
20. Nore BF, Vargas L, Mohamed AJ, et al. Redistribution of Bruton's tyrosine kinase by activation of phosphatidylinositol 3-kinase and Rho-family GTPases. Eur J Immunol 2000;30:145-54 (Pubitemid 30011775)
21. Mohamed AJ, Vargas L, Nore BF, et al. Nucleocytoplasmic shuttling of Bruton's tyrosine kinase. J Biol Chem 2000;275:40614-19 (Pubitemid 32064701)
22. Rawlings DJ, Scharenberg AM, Park H, et al. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science 1996;271:822-5 (Pubitemid 26058937)
23. Afar DE, Park H, Howell BW, et al. Regulation of Btk by Src family tyrosine kinases. Mol Cell Biol 1996;16:3465-71 (Pubitemid 26199865)
24. Cheng G, Ye ZS, Baltimore D. Binding of Bruton's tyrosine kinase to Fyn, Lyn, or Hck through a Src homology 3 domain-mediated interaction. Proc Natl Acad Sci USA 1994;91:8152-5 (Pubitemid 24253904)
25. Humphries LA, Dangelmaier C, Sommer K, et al. Tec kinases mediate sustained calcium influx via site-specific tyrosine phosphorylation of the phospholipase Cgamma Src homology 2-Src homology 3 linker. J Biol Chem 2004;279:37651-61 (Pubitemid 39195478)
26. Yu L, Mohamed AJ, Simonson OE, et al. Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB. Blood 2008;111:4617-26
27. Satterthwaite AB, Witte ON. The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev 2000;175:120-7 (Pubitemid 30427162)
28. Uckun FM. Bruton's tyrosine kinase (BTK) as a dual-function regulator of apoptosis. Biochem Pharmacol 1998;56:683-91 (Pubitemid 28454578)
29. Islam TC, Smith CI. The cellular phenotype conditions Btk for cell survival or apoptosis signaling. Immunol Rev 2000;178:49-63 (Pubitemid 32095219)
30. Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007;2:58-61
31. Ponader S, O'Brien S, Wierda W, et al. Bruton's tyrosine kinase inhibitor PCI-32765 Abrogates BCR-and Nurselike Cell-Derived activation of CLL cells in vitro and in vivo [ASH annual meeting abstract 45]. Blood 2010;116:21
32. Balasubramanian S, Honigberg L, Tee L, Mamuszka H. Identification of MicroRNA markers of sensitivity to the novel Bruton's Tyrosine Kinase (BTK) inhibitor PCI-32765 in non-Hodgkin's lymphoma [ASH annual meeting abstract 3366]. Blood 2008;112:11
33. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010;107:13075-80
34. Chang BY, Huang MM, Francesco M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther 2011;13:R115
35. Breen M, Modiano JF. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans-man and his best friend share more than companionship. Chromosome Res 2008;16:145-54 (Pubitemid 351294788)
36. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011;117:23-6287-96
37. Herman S, Mahoney E, Jaglowski S, et al. The kinase inhibitor, PCI-32765, demonstrates activity in chronic lymphocytic leukemia cells independent of microenvironmental survival signals [ASH annual meeting Abst 1385]. Blood 2010;116:21
38. Reittie JE, Yong KL, Panayiotidis P, Hoffbrand AV. Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia. Leuk Lymphoma 1996;22:83-90; follow 186, color plate VI (Pubitemid 26177722)
39. Panayiotidis P, Ganeshaguru K, Jabbar SA, Hoffbrand AV. Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1993;85:439-45 (Pubitemid 23349043)
40. Konopleva M, Andreeff M. Targeting the leukemia microenvironment. Curr Drug Targets 2007;8:685-701 (Pubitemid 47603399)
41. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008;14:2519-26
42. Byrd C. Blum K, Burger J, et al Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study [ASCO Annual Meeting abstract 6508]. JCO 2011;29:15
43. Burger J, Fowler N, Ranjana A, et al. The Bruton's tyrosine kinase inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): an Update on Ongoing Phase 1 Studies [ASH Annual Meeting abstract 57]. Blood 2010;116:21
44. Advani R, Smith D. Boyd, B, et al. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: evidence of antitumor activity from a phase I study [ASCO Annual Meeting abstract 8012]. JCO 2010;15-Suppl
45. Fowler N, Sonali M, Smith B, et al. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with Relapsed/Refractory BCell malignancies: results From a Phase I Study [ASH annual meeting abstract 964]. Blood 2010;116:21
46. Wierda WG, Kipps TJ, Durig J, et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011;117:6450-8
47. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-21
48. Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009;20:520-5
49. Coutre S. Furman, J, Brown, D, et al. Phase I study of CAL-101, an isoformselective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia [ASCO Annual Meeting abstract 6631]. JCO 2011;29:15
50. Flinn I, Leonard C. Wagner-Johnston, S, et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 {delta}, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies [ASCO Annual Meeting abstract 3064]. JCO 2011;29:15
51. Rui L, Schmitz R, Ceribelli M, Staudt LM. Malignant pirates of the immune system. Nat Immunol 2011;12:933-40